The United Kingdom’s antirheumatic drug market was valued at US$4.33 billion in 2020. The market is projected to grow at a CAGR of 3.93% to attain a value of US$5.66 billion by 2027.
The market in the United Kingdom is projected to show nominal growth over the next five years on account of the high prevalence of rheumatic diseases in the country coupled with the presence of a world-class healthcare sector in the country. According to the United Kingdom’s National Health Service, more than 10 million people in the country suffer from arthritis and numerous other conditions. This, in turn, is anticipated to significantly drive the demand for various types of anti-rheumatic drugs and thus positively impact the market growth in the country in the coming years. Furthermore, the growing healthcare expenditure further enables the citizens to avail of costly treatments and medicines, which is also projected to positively impact the market growth in the United Kingdom throughout the forecast period.
Additionally, with the growing number of geriatric people, aged 65 years and above in the United Kingdom, the number of age-associated diseases such as joint pain, back pain, and rheumatoid arthritis, among others, will also continue to soar, hence the market for various types of antirheumatic drugs will also soar due to their requirement for disease treatment. According to the World Bank estimates, the geriatric population (65 years of age or older) in the United Kingdom has grown from a population size of 11.706 million in 2015 to a population size of 12.231 million in 2018.
The United Kingdom’s antirheumatic drug market has been segmented on the basis of the type of disease, type of molecule, and sales channel. Type of disease, the market has been classified on the basis of osteoarthritis, rheumatoid arthritis, gout, lupus, and others. The market has been segmented based on molecule type; the market has been segmented based on pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC).
United Kingdom Anti-Rheumatic Drug Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2020 | USD 4.33 billion |
| Total Market Size in 2027 | USD 5.66 billion |
| Forecast Unit | Billion |
| Growth Rate | 3.93% |
| Study Period | 2015 to 2027 |
| Historical Data | 2015 to 2018 |
| Base Year | 2019 |
| Forecast Period | 2020 – 2027 |
| Segmentation | Type of Disease, Drug Class, Sales Channel |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
Segments
- Type of Disease
- Drug Class
- Sales Channel
Table of Contents
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.4. Industry Value Chain Analysis
5. UNITED KINGDOM ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. UNITED KINGDOM ANTI-RHEUMATIC DRUG MARKET ANALYSIS, DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others
7. UNITED KINGDOM ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. AbbVie Inc.
9.2. Amget Inc.
9.3. Johnson and Johnson
9.4. Pfizer Inc.
9.5. GlaxoSmithKline plc
9.6. Merck & Co., Inc.
9.7. Eli Lilly and Company
9.8. Novartis AG
9.9. Celgene Corporation (Bristol-Myers Squibb)
Frequently asked questions
What is the current and projected market value of the United Kingdom Anti-Rheumatic Drug Market?
The United Kingdom's anti-rheumatic drug market was valued at US$4.33 billion in 2020. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.93%, reaching an estimated value of US$5.66 billion by 2027.
What are the primary factors driving the growth of the UK Anti-Rheumatic Drug Market during the forecast period (2022-2027)?
The United Kingdom Anti-Rheumatic Drug Market's growth is primarily driven by the high prevalence of rheumatic diseases, with over 10 million people in the UK suffering from arthritis and related conditions. Additionally, a world-class healthcare sector, growing healthcare expenditure enabling access to costly treatments, and an increasing geriatric population contribute significantly to market expansion.
How is the United Kingdom Anti-Rheumatic Drug Market segmented in the report?
The report segments the market based on the type of disease, including Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, and others. Further segmentation covers molecule types such as pharmaceuticals and biopharmaceuticals, and sales channels, distinguishing between prescription and over-the-counter (OTC) drugs.
What was the impact of the COVID-19 pandemic on the United Kingdom Anti-Rheumatic Drug Market?
The COVID-19 pandemic initially had a negative impact on the UK anti-rheumatic drug market. However, certain DMARDs and biologics routinely used for rheumatoid arthritis, such as hydroxychloroquine, sarilumab, tocilizumab, and anakinra, were studied as potential COVID-19 treatments, which subsequently boosted growth prospects for manufacturers of these specific medications during the anticipated period.
How does the increasing geriatric population contribute to the demand for anti-rheumatic drugs in the UK?
The growing number of people aged 65 and above in the United Kingdom directly correlates with a rise in age-associated conditions like joint pain, back pain, and rheumatoid arthritis. This demographic shift necessitates increased demand for various anti-rheumatic drugs for disease treatment, thereby significantly driving market growth.
What strategic insights does the report offer for understanding future opportunities in the UK anti-rheumatic drug sector?
The report provides insights into key growth opportunities stemming from the high prevalence of rheumatic diseases and the robust healthcare infrastructure. It highlights the strategic importance of growing healthcare expenditure and demographic shifts, such as the increasing geriatric population, in shaping future market demand and potential for drug innovation across different molecule types and sales channels.
Cite this report
Knowledge Sourcing Intelligence. (Mar 2026). United Kingdom Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2022-2027). https://www.knowledge-sourcing.com/report/united-kingdom-anti-rheumatic-drug-market





